Cargando…
An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
Numerous assays evaluating serological and cellular responses have been developed to characterize immune responses against SARS-CoV-2. Serological assays are both cost- and time-effective compared to cellular assays, but cellular immune responses may provide a diagnostic value to determine previous...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483319/ https://www.ncbi.nlm.nih.gov/pubmed/34591918 http://dx.doi.org/10.1371/journal.pone.0258041 |
_version_ | 1784577096006238208 |
---|---|
author | Mangsbo, Sara M. Havervall, Sebastian Laurén, Ida Lindsay, Robin Jernbom Falk, August Marking, Ulrika Lord, Martin Buggert, Marcus Dönnes, Pierre Christoffersson, Gustaf Nilsson, Peter Hober, Sophia Phillipson, Mia Klingström, Jonas Thålin, Charlotte |
author_facet | Mangsbo, Sara M. Havervall, Sebastian Laurén, Ida Lindsay, Robin Jernbom Falk, August Marking, Ulrika Lord, Martin Buggert, Marcus Dönnes, Pierre Christoffersson, Gustaf Nilsson, Peter Hober, Sophia Phillipson, Mia Klingström, Jonas Thålin, Charlotte |
author_sort | Mangsbo, Sara M. |
collection | PubMed |
description | Numerous assays evaluating serological and cellular responses have been developed to characterize immune responses against SARS-CoV-2. Serological assays are both cost- and time-effective compared to cellular assays, but cellular immune responses may provide a diagnostic value to determine previous SARS-CoV-2 infection in seronegative individuals. However, potential cross-reactive T cell responses stemming from prior encounters with human coronaviruses (HCoVs) may affect assay specificity. In this study, we evaluated the specificity and sensitivity of a SARS-CoV-2 IFN-γ Release Assay (IGRA) based on the FluoroSpot method employing commercially available SARS-CoV-2-specific peptide pools, as well as an in-house designed SARS-CoV-2 peptide pool restricted to 5 amino acid stretches or less aligning with endemic HCoVs. Blood samples were obtained from healthcare workers (HCW) 5–6 months post SARS-CoV-2 spike (S) IgG and nucleocapsid (N) IgG dual seroconversion (n = 187) and HCW who had been S IgG and N IgG dual seronegative at repeated occasions, including the current sampling time point (n = 102). In addition, samples were obtained 4 to 5 months post infection from 55 polymerase chain reaction (PCR)-confirmed COVID-19 patients. Assay specificity and sensitivity were calculated with serology as a reference standard for HCW. The in-house generated peptide pool displayed a specificity of 96.1%, while the commercially available peptide pools displayed specificities of 80.4% and 85.3%, respectively. Sensitivity was higher in a cohort of previously hospitalized COVID-19 patients (96.4% and 84.0% for the commercially available peptide pools and 92.7% for the in-house generated peptide pool) compared to the HCW cohort (92.0% and 66.8% for the commercially available peptide pools and 76.0% for the in-house generated peptide pool). Based on these findings, the individual diagnostic value of T cell immune responses against SARS-CoV-2 currently appears to be limited but remain an important research tool ahead. |
format | Online Article Text |
id | pubmed-8483319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84833192021-10-01 An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses Mangsbo, Sara M. Havervall, Sebastian Laurén, Ida Lindsay, Robin Jernbom Falk, August Marking, Ulrika Lord, Martin Buggert, Marcus Dönnes, Pierre Christoffersson, Gustaf Nilsson, Peter Hober, Sophia Phillipson, Mia Klingström, Jonas Thålin, Charlotte PLoS One Research Article Numerous assays evaluating serological and cellular responses have been developed to characterize immune responses against SARS-CoV-2. Serological assays are both cost- and time-effective compared to cellular assays, but cellular immune responses may provide a diagnostic value to determine previous SARS-CoV-2 infection in seronegative individuals. However, potential cross-reactive T cell responses stemming from prior encounters with human coronaviruses (HCoVs) may affect assay specificity. In this study, we evaluated the specificity and sensitivity of a SARS-CoV-2 IFN-γ Release Assay (IGRA) based on the FluoroSpot method employing commercially available SARS-CoV-2-specific peptide pools, as well as an in-house designed SARS-CoV-2 peptide pool restricted to 5 amino acid stretches or less aligning with endemic HCoVs. Blood samples were obtained from healthcare workers (HCW) 5–6 months post SARS-CoV-2 spike (S) IgG and nucleocapsid (N) IgG dual seroconversion (n = 187) and HCW who had been S IgG and N IgG dual seronegative at repeated occasions, including the current sampling time point (n = 102). In addition, samples were obtained 4 to 5 months post infection from 55 polymerase chain reaction (PCR)-confirmed COVID-19 patients. Assay specificity and sensitivity were calculated with serology as a reference standard for HCW. The in-house generated peptide pool displayed a specificity of 96.1%, while the commercially available peptide pools displayed specificities of 80.4% and 85.3%, respectively. Sensitivity was higher in a cohort of previously hospitalized COVID-19 patients (96.4% and 84.0% for the commercially available peptide pools and 92.7% for the in-house generated peptide pool) compared to the HCW cohort (92.0% and 66.8% for the commercially available peptide pools and 76.0% for the in-house generated peptide pool). Based on these findings, the individual diagnostic value of T cell immune responses against SARS-CoV-2 currently appears to be limited but remain an important research tool ahead. Public Library of Science 2021-09-30 /pmc/articles/PMC8483319/ /pubmed/34591918 http://dx.doi.org/10.1371/journal.pone.0258041 Text en © 2021 Mangsbo et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Mangsbo, Sara M. Havervall, Sebastian Laurén, Ida Lindsay, Robin Jernbom Falk, August Marking, Ulrika Lord, Martin Buggert, Marcus Dönnes, Pierre Christoffersson, Gustaf Nilsson, Peter Hober, Sophia Phillipson, Mia Klingström, Jonas Thålin, Charlotte An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses |
title | An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses |
title_full | An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses |
title_fullStr | An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses |
title_full_unstemmed | An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses |
title_short | An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses |
title_sort | evaluation of a fluorospot assay as a diagnostic tool to determine sars-cov-2 specific t cell responses |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483319/ https://www.ncbi.nlm.nih.gov/pubmed/34591918 http://dx.doi.org/10.1371/journal.pone.0258041 |
work_keys_str_mv | AT mangsbosaram anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT havervallsebastian anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT laurenida anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT lindsayrobin anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT jernbomfalkaugust anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT markingulrika anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT lordmartin anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT buggertmarcus anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT donnespierre anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT christofferssongustaf anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT nilssonpeter anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT hobersophia anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT phillipsonmia anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT klingstromjonas anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT thalincharlotte anevaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT mangsbosaram evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT havervallsebastian evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT laurenida evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT lindsayrobin evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT jernbomfalkaugust evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT markingulrika evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT lordmartin evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT buggertmarcus evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT donnespierre evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT christofferssongustaf evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT nilssonpeter evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT hobersophia evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT phillipsonmia evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT klingstromjonas evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses AT thalincharlotte evaluationofafluorospotassayasadiagnostictooltodeterminesarscov2specifictcellresponses |